Compare Crispr Therapeutics AG (CRSP) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PepsiCo, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.79 (market cap $5.23B), while PepsiCo, Inc. trades at $138.12 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 36.1× Crispr Therapeutics AG's market cap, and PepsiCo, Inc. pays a 4.28% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PEP | |
|---|---|---|
Market Cap | $5.23B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $170.44 |
52-Week Low | $44.34 | $134.95 |
Enterprise Value | $3.65B | $231.41B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong fundamentals with $93.93B revenue in 2025, 10.78% net margin, and consistent dividend payments. Recent news highlights price adjustments for snack products and sponsorship withdrawals, while analysts project 15% upside to the $158.79 consensus target.
PepsiCo presents a mixed outlook with solid fundamentals and dividend yield offset by near-term price pressure and competitive challenges. The stock offers value at current levels for income investors, though execution risks in North America and consumer pricing sensitivity require monitoring. Wall Street maintains cautious optimism with 64% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
